Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Soriot concerned 'distraction' of a Pfizer merger will damage pipeline prospects

This article was originally published in Scrip

Executive Summary

AstraZeneca has rebuffed Pfizer's overtures, citing undervaluation, but in the most recent update, CEO Pascal Soriot claims his major concern is that the "distraction" of a megamerger would have a "big negative impact" on the pipeline: a pipeline with ambitious forecasts. AstraZeneca has released the company's long-range plan for 2014 to 2023 which forecasts annual revenues of more than $45bn by 2023. The company had revenues of $25.7bn in 2013, prompting some analysts to suggest AstraZeneca is being overly optimistic.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts